Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured marketing approval in China for its innovative Vispearl drug-loaded microsphere product. This product is designed for use in the embolization treatment of malignant tumors within vascular-rich parenchymal organs and is recognized as the first of its kind globally.
The Vispearl drug-loaded microsphere builds upon traditional drug-loaded microspheres and is manufactured using a patented iodine-containing developing molecule, triiodobenzoic acid, which serves as a contrast agent in x-rays, combined with a critical phase plane crosslinking process. With a minimum specification of 40 microns, these microspheres address the clinical need for precise end-embolization and overcome the limitations of traditional microsphere particle sizes that are too large for peripheral embolization and postoperative imaging.- Flcube.com
